To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

PHASE3UnknownINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

December 31, 2002

Study Completion Date

August 31, 2004

Conditions
Lupus
Interventions
DRUG

Prasterone (GL701)

Trial Locations (26)

10461

Albert Einstein Medical School, The Bronx

11030

North Shore University Hospital, Division of Rheumatology, Manhasset

11203

SUNY Downstate Medical Center, Brooklyn

14000

Immunology/Rheumatology Instituto Nacional de Ciencias Medicas y Nutricion, S.Z., Mexico City

15261

University of Pittsburgh, Pittsburgh

16635

Altoona Center for Clinical Research, Duncansville

21205

Johns Hopkins University, Baltimore

23462

Sentara Medical Group DBA, Virginia Beach

33334

Center for Rheumatology, Immunology and Arthritis, Fort Lauderdale

33614

Tampa Medical Group, P.A., Tampa

37232

Vanderbilt University, Nashville

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

65804

St. John's Medical Research Group, Springfield

70121

Ochsner Clinic Foundation, New Orleans

74114

Oklahoma Center for Arthritis Therapy, Tulsa

77555

University of Texas, Medical Branch, Galveston

85724

University of Arizona, Tucson

90048

Wallace Rheumatic Study Center, Los Angeles

91607

Peng T Fan, MD & Wonil Lee, MD Partnership, North Hollywood

92270

Lifestyles Health Science Center, Rancho Mirage

94578

East Bay Rheumatology Group, San Leandro

97201

Oregon Health & Science University, Portland

98104

Seattle Rheumatology Associates, Seattle

92093-0943

University of California San Diego, San Diego

32806-6264

Rheumatology Associates of Central Florida, Orlando

Sponsors
All Listed Sponsors
lead

Genelabs Technologies

INDUSTRY